GCG and Hypoglycemia: Across the hypoglycemic challenges, a statistically significant effect of SSTR2a was observed: delayed onset of hypoglycemia (challenges 1 and 2 only), higher blood glucose nadir and reduced hypoglycemia exposure (area under the curve [AUC] of blood glucose <3.9 mmol/L) (P < .05 for all parameters), with a larger overall glucagon response in SSTR2a-treated rats (P < .0001 for glucagon parameters) compared to vehicle-treated rats.